主要文件

查看所有文档

553511

Rac1 Inhibitor II

Name: Rac1 Inhibitor II
Brand: MM

The Rac1 Inhibitor II, also referenced under CAS 1090893-12-1, controls the biological activity of Rac1. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

别名:

Rac1 Inhibitor II, 3-((3,5-Dimethylisoxazol-4-yl)methoxy)-N-(4-methyl-3-sulfamoyl-phenyl)benzamide, Z62954982

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₂₀H₂₁N₃O₅S

化学文摘社编号:

1090893-12-1

分子量:

415.46

MDL number:

MFCD00001079

NACRES:

NA.77

UNSPSC Code:

12352200

Assay:

≥93% (HPLC)

Form:

solid

Quality level:

100

Storage condition:

OK to freeze, protect from light

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

Quality Level

100

assay

≥93% (HPLC)

form

solid

manufacturer/tradename

Calbiochem^®

storage condition

OK to freeze, protect from light

color

off-white

solubility

DMSO: 100 mg/mL

shipped in

ambient

storage temp.

2-8°C

说明

General description

A cell-permeable isoxazolyl-benzamide compound that is more effective than NSC23766 (Cat. Nos. 553502 & 553508) in inhibiting PDGF-BB- (Cat. No. 521225) induced cellular Rac1 activation (45.8% vs 11.1% inhibition by 4 h pretreatment of the respective compound at 50 µM) in serum-starved SMCs (human aortic smooth muscle cells) by interfering Rac1-Tiam1 interaction, while exhibiting no effect toward cellular Cdc42 and RhoA activation or Rac1 interaction to its effector Pak1. Shown to effectively prevent PDGF-BB-induced membrane ruffling and lamellipodia formation in serum-starved 3T3 cells (4 h pretreatment at 25 µM). Also available in InSolution format (Cat. No. 553512).

Packaging

Packaged under inert gas

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Standard Handling (A)

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

分析证书(COA)

输入产品批号来搜索分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Dual blockade of macropinocytosis and asparagine bioavailability shows synergistic anti-tumor effects on KRAS-mutant colorectal cancer.

Keita Hanada et al.

Cancer letters, 522, 129-141 (2021-09-21)

Mutations of KRAS gene are found in various types of cancer, including colorectal cancer (CRC). Despite intense efforts, no pharmacological approaches are expected to be effective against KRAS-mutant cancers. Macropinocytosis is an evolutionarily conserved actin-dependent endocytic process that internalizes extracellular

全球贸易项目编号

货号	GTIN
553511-10MG	04055977193701